NCT03682055View on ClinicalTrials.gov

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

June 23, 2020

Study Completion Date

August 8, 2020

Conditions
Nasopharyngeal CarcinomaNasopharyngeal Cancer
Interventions
DRUG

VK-2019

EBNA1 inhibitor

Trial Locations (6)

77030

The University of Texas - MD Anderson Cancer Center, Houston

94305

Stanford University, School of Medicine, Stanford Cancer Institute, Stanford

94800

Institut Gustave Roussy, Villejuif

169610

National Cancer Centre Singapore, Singapore

510060

Sun Yat Sen University Cancer Center, Guangzhou

Unknown

Hong Kong University - Queen Mary Hospital, Hong Kong

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Cullinan Therapeutics Inc.

INDUSTRY

NCT03682055 - Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | Biotech Hunter | Biotech Hunter